High Carbohydrate 19-9 Antigen Serum Levels in Patients with Nonmelanoma Skin Cancer and Primary Occult Cancer
Authors:
- Giulia MalaguarneraGiulia Malaguarnera
- Saverio LatteriSLSaverio Latteri
- Roberto MadedduRoberto Madeddu
- Vito Emanuele CataniaVCVito Emanuele Catania
- Gaetano BertinoGBGaetano Bertino
- Rosario Emanuele PerrottaRPRosario Emanuele Perrotta
- Francesco DinottaFDFrancesco Dinotta
- Michele MalaguarneraMMMichele Malaguarnera
Open Access
- 3 August 2020
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 8 (8) , 265
Abstract
Background: Non-melanoma skin cancers (NMSC), despite having a favourable prognosis, present an increased risk of occult malignancies. The aim of this study was the evaluation of the usefulness of the mucinous marker carbohydrate 19-9 antigen (CA 19-9) in the diagnosis of occult cancers. (1) Patients and Methods: This is a case control study in which 480 patients with NMSC and 480 matched control subjects with dermatitis were enrolled; 208 patients with NMSC showed upper-normal CA 19-9 values, and 272 showed under-normal CA 19-9 values. (2) Results: The 208 patients positive for CA 19-9 included 87 with basal cell carcinoma (BCC) and 121 with squamous cell carcinoma (SCC). The 272 patients negative for CA 19-9 included 107 with BCC and 165 with SCC. For the SCC patients, CA 19-9 serum levels were significant in 121 of the patients (positive), 66 of which were affected by cancer; CA 19-9 was within the normal range in 165 patients, of which 30 were diagnosed with cancer. In the SCC patients, the CA 19-9 sensitivity was 68%, the specificity was 70%, the positive predictive value (PPV) was 54% (95%) and the negative predictive value (NPV) was 81%. In the BCC patients, the CA 19-9 sensitivity was 70%, the specificity was 66%, the PPV was 48% and the NPV was 83%. In the dermatitis patients (controls), we observed 121 patients that were CA 19-9 positive, with 15 malignancies, and 359 CA 19-9-negative patients, with three malignancies. (3) Conclusions: To confirm the association between CA 19-9 and an elevated risk of malignancies in NMSC, prospective cohort studies should be performed.Keywords
This publication has 53 references indexed in Scilit:
- Carbohydrate 19.9 Antigen Serum Levels in Liver DiseaseBioMed Research International, 2013
- Centenarians and supercentenarians: a black swan. Emerging social, medical and surgical problemsBMC Surgery, 2012
- Adjusting CA19-9 values to predict malignancy in obstructive jaundice: Influence of bilirubin and C-reactive proteinWorld Journal of Gastroenterology, 2012
- Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive ReviewIndian Journal of Surgical Oncology, 2011
- Nonmelanoma Skin Cancer and the Risk of Second Primary Cancers: a Systematic ReviewCancer Epidemiology, Biomarkers & Prevention, 2010
- Serum markers of cutaneous melanomaFrontiers in Bioscience-Elite, 2010
- Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status reportAnnals of Oncology, 2009
- Skin Cancers after Organ TransplantationNew England Journal of Medicine, 2003
- Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundiceEuropean Journal of Surgical Oncology, 2000
- Prospective Evaluation of the Diagnostic Efficacy of CA 19–9 Assay as a Marker for Gastrointestinal CancersDigestion, 1986